CoChat

The emerging role of epigenetic therapeutics in immuno-oncology

Open access

The DOI matches its Crossref record; 274 of the 277 references it cites were found in a registry or an index.

Abstract

The past decade has seen the emergence of immunotherapy as a prime approach to cancer treatment, revolutionizing the management of many types of cancer. Despite the promise of immunotherapy, most patients do not have a response or become resistant to treatment. Thus, identifying combinations that potentiate current immunotherapeutic approaches will be crucial. The combination of immune-checkpoint inhibition with epigenetic therapy is one such strategy that is being tested in clinical trials, encompassing a variety of cancer types. Studies have revealed key roles of epigenetic processes in regulating immune cell function and mediating antitumour immunity. These interactions make combined epigenetic therapy and immunotherapy an attractive approach to circumvent the limitations of immunotherapy alone. In this Review, we highlight the basic dynamic mechanisms underlying the synergy between immunotherapy and epigenetic therapies and detail current efforts to translate this knowledge into clinical benefit for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-019-0266-5

Cites

274 of 274 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 274 references

Research works printed but not linked: 1

  1. Allis, C. D., Jenuwein, T., Reinberg, D. & Caparros, M. in Epigenetics 2nd edn (Cold Spring Harbor Laboratory Research Press, 2015).

Cited by

See all 444

Metadata

Authors
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B.
Affiliations
Johns Hopkins University (US)
Corresponding author
Baylin, Stephen B.
Venue
Nature Reviews Clinical Oncology
Published
2019-09-23
Volume
17
Issue
2
Pages
75-90
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W2974304113
Cited by
433
References
277
Citations by year
2026: 46 · 2025: 55 · 2024: 72 · 2023: 71 · 2022: 81 · 2021: 77 · 2020: 31
FWCI
4.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (P30CA006973)
  • National Institute of General Medical Sciences (T32GM008752)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
epigenetic therapy, cancer immunotherapy, immune checkpoint inhibitors, combination immunotherapy, antitumor immunity, immune cell function, epigenetic drugs, cancer immunotherapy resistance, clinical trials
MeSH terms
Humans, Immunotherapy, Medical Oncology, Neoplasms, Epigenesis, Genetic, Epigenomics, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The emerging role of epigenetic therapeutics in immuno-oncology. https://app.cochat.ai/papers/10.1038/s41571-019-0266-5
The paper
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020). The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-019-0266-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.